miR-145-5p suppresses cell proliferation by targeting IGF1R and NRAS genes in multiple myeloma cells

Author:

Kaya Murat1ORCID,Suer Ilknur12ORCID,Ozgur Emre3ORCID,Capik Ozel45ORCID,Karatas Omer Faruk45ORCID,Ozturk Sukru1ORCID,Gezer Ugur3ORCID,Palanduz Sukru1ORCID,Cefle Kivanc1ORCID

Affiliation:

1. Department of Internal Medicine , Division of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University , Istanbul , Türkiye

2. Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University , Istanbul , Türkiye

3. Department of Basic Oncology , Diagnostic Treatment and Care Services, Oncology Institute, Istanbul University , Istanbul , Türkiye

4. Department of Molecular Biology and Genetics , Erzurum Technical University , Erzurum , Türkiye

5. Molecular Cancer Biology Laboratory , High Technology Application and Research Center, Erzurum Technical University , Erzurum , Türkiye

Abstract

Abstract Objectives Multiple myeloma (MM) is a common hematological cancer. Hence, it is important to conduct further studies investigating the molecular mechanisms in detail that contributes to myeloma genesis. In addition to genetic changes, epigenetic factors such as miRNAs may influence the expression of myeloma-related genes. Methods Our study aimed to detect genes closely related to MM and miRNAs involved in the cancer process by changing the expression of these genes with bioinformatics tools and in vitro methods. Bioinformatics approaches identified hub miRNAs in our study that may have a role in the expression change of genes connected to myeloma. The functional impacts of the chosen miRNA on RPMI8226 and U266 cell lines and the effect of this miRNA on the expression changes of putative target genes were investigated. Results The viability of miR-145-5p transfected cells was found to decrease compared to control cells and the expression of IGF1R and NRAS genes were found to be significantly suppressed in both cell lines at mRNA level. Decreased levels of the IGF1R and NRAS genes were confirmed in miR-145-5p transfected cells at the protein level as well as compared to control cells. In addition, IGF1R/miR-145-5p interaction was demonstrated via luciferase reporter assay. However, expression levels of EGFR, KLF4, IRS1, CDK4 and CDK6 candidate genes had no statistically significant difference in miR-145-5p transfected cells compared to control cells. Conclusions Mir-145-5p was demonstrated to act as a tumor suppressor miRNA and inhibit the proliferation in MM cell lines via targeting IGF1R and NRAS.

Funder

Istanbul University Scientific Research Projects Coordination

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry (medical),Clinical Biochemistry,Molecular Biology,Biochemistry

Reference32 articles.

1. Lonial, S, Mitsiades, CS, Richardson, PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011;17:1264–77. https://doi.org/10.1158/1078-0432.ccr-10-1805.

2. Suer, I, Aday, A, Sariman, M, Ayer, M, Yonal Hindilerden, I, Sirma Ekmekci, S, et al.. Dysregulation of MS4A3 and PRDX5 gene expression in multiple myeloma patients. Int J Hematol Oncol UHOD 2021;31:205–13.

3. Badros, A, Hyjek, E, Ma, N, Lesokhin, A, Dogan, A, Rapoport, AP, et al.. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood 2017;130:1189–97. https://doi.org/10.1182/blood-2017-03-775122.

4. Bartel, DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97. https://doi.org/10.1016/s0092-8674(04)00045-5.

5. Xu, WX, Liu, Z, Deng, F, Wang, DD, Li, XW, Tian, T, et al.. MiR-145: a potential biomarker of cancer migration and invasion. Am J Transl Res 2019;11:6739–53.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3